Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Beverly Kyalwazi(University of Chicago), Laura J. Esserman(University of California, San Francisco), Rita Nanda(University of Chicago), Erin M. Ellis, Andres Forero‐Torres(Kirklin Clinic), Laura van ‘t Veer, Barbara Haley(Shaanxi Research Association for Women and Family), Lajos Pusztai(Yale University), Scott Berry(Queen's University), Amy Wilson(Quantum Leap Healthcare Collaborative), Qamar J. Khan(University of Kansas Medical Center), Rachel L. Yung(Seattle Cancer Care Alliance), Judy C. Boughey(Mayo Clinic in Arizona), Nola M. Hylton(University of California, San Francisco), Anne Blaes(University of Minnesota), Smita Asare(Quantum Leap Healthcare Collaborative), Donald W. Northfelt(Mayo Clinic in Arizona), Kristen K. Edmiston(Nova Medical (United States)), A. Jo Chien(University of California, San Francisco), Hyo S. Han(Moffitt Cancer Center), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Rebecca K. Viscusi(University of Arizona), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Anne M. Wallace(University of California San Diego), Fraser Symmans(The University of Texas MD Anderson Cancer Center), Ashish Sanil(Berry & Associates (United States)), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Olufunmilayo Olopade(University of Chicago), Michelle Melisko(University of California, San Francisco), A. Elias(University of Colorado Denver), Hope Rugo(University of California, San Francisco)
Cited by 3
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k